The results of this study showed that white matter was more sensitive to hypoglycemia than previously thought and there was no specific association between the patterns of injury and clinical outcomes whether the cerebral cortex, deep gray matter, and/or white matter were affected. Diffuse and extensive injury observed on the DWI predicts a poor neurologic outcome in patients with hypoglycemic injuries.
The five patients with brown tumor demonstrated a wide spectrum of MR imaging findings. There are few lesions that are osteolytic on the radiographs and that show a short T2 on MR imaging, such as brown tumor. Multiple cystic or mixed lesions are the expected findings of brown tumors.
Purpose: To evaluate the feasibility of low-dose, 3D timeresolved contrast-enhanced magnetic resonance angiography (TR-CEMRA) in the assessment of the supraaortic vessel, and to compare the results with high-resolution contrast-enhanced MRA (HR-CEMRA).
Materials and Methods:This was an Institutional Review Board-approved retrospective study. Forty-five consecutive patients underwent contrast-enhanced 3D TR-CEMRA and 3D HR-CEMRA for evaluation of neurovascular disease at 3.0 T. Gadobutrol was administered at a constant dose of 1 mL for TR-CEMRA (independent of patient weight), and 0.1 mmol/kg for HR-CEMRA. Two readers evaluated image quality using a four-point scale (from 0 ¼ excellent to 3 ¼ nondiagnostic), and subsequently graded each stenosis into clinically relevant categories: normal (0%), mild stenosis (<50%), moderate to severe (>50%), and occlusion.
Results:The overall image quality for low-dose TR-CEMRA was in the diagnostic range (median 0, range 0-3). On the grading of stenosis, TR-CEMRA using the TWIST sequence correlated with HR-CEMRA (r ¼ 0.668, P < 0.001). In terms of the comparison of TR-CEMRA with HR-CEMRA, of the 675 supraaortic arterial segments evaluated for stenosis or occlusion, agreement occurred in 611 of 675 (90.5%), overestimation in 41 of 675 (6.1%), and underestimation 23 of 675 (3.4%).Conclusion: TR-CEMRA achieved by administration of a small contrast dose (1 cc) yields rapid and important functional and anatomical information in the evaluation of supraaortic arteries. Due to limited spatial resolution, TR-CEMRA at the current parameters has a tendency to overestimate the stenosis of smaller intracranial arteries compared to HR-CEMRA.
ObjectiveTo assess the feasibility and safety of polyvinyl alcohol (PVA) embolization adjuvant to transarterial oily chemoembolization (P-TACE) in advanced hepatocellular carcinoma (HCC) with arterioportal shunts (APS).Materials and MethodsNineteen patients who underwent PVA embolization for APS before a routine chemoembolization (TACE) procedure were retrospectively reviewed. 10 of these 19 patients underwent follow-up TACE or P-TACE after P-TACE (Group A), but nine patients underwent only initial P-TACE because of progression of HCC and/or underlying liver cirrhosis (Group B). Hepatic function tests, APS grades, and portal flow directions were evaluated before and after P-TACE sessions. Complications after procedures and survival days were also evaluated.ResultsIn group A, APS grade was improved in eight patients and five of six patients with hepatofugal flow showed restored hepatopetal flow postoperatively. No immediate complication was developed in either group. Transient hepatic insufficiency developed in eight (42.1%) of 19 patients after P-TACE, and seven (87.5%) of these eight recovered within two weeks under conservative care. The mean and median survival time all study subjects was 280 days and 162 days.ConclusionP-TACE is feasible and safe in advanced HCC patients with APS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.